



Biotech Capital (BTC) - ASX Announcement

1 September 2015

Share Placement and Change in Board Composition

Biotech Capital Limited (ASX:BTC) announced today that it has agreed to issue 12,860,583 shares at 8c per share as a placement within the Company's existing placement capacity. These shares will be placed with Auckland Trust Company Limited, which is an associated party to Mr Lang Walker. The funds raised (\$1,028,847 before issue expenses) will be used for working capital.

We advise that Mr Bruce Hancox and Mr Jon Pilcher will join the Board as non-executive Directors effective from 1 September 2015.

Mr Hancox has had a long and distinguished career in business in New Zealand and Australia. He was for many years involved with Brierley Investments Limited as General Manager, Group CEO and Chairman. Bruce is currently a director of Neuren Pharmaceuticals Limited and Medical Australia Limited.

Mr Pilcher is a Chartered Accountant and holds a degree in biotechnology from Reading University in the UK. He was previously the CFO and Company Secretary of Acrux Limited for eleven years and brings a wealth of experience in a wide range of matters relating to the funding, growth and compliance of a registered Pooled Development Fund. Jon is currently the CFO and Company Secretary of Neuren Pharmaceuticals Limited.

With the addition of these new Directors to the Board, we advise that Mr Alastair Davidson has agreed to resign as a director of the Company effective from 1 September 2015. We gratefully acknowledge Alastair's 15 years service to the Company and we extend our very best wishes to him for his future endeavours.

Biotech Capital's Chairman Richard Treagus commented, "We are very pleased to take this opportunity to strengthen the Board, our shareholder base and the financial position of the Company. In doing so, we are in a good position to execute on our stated strategy of making carefully targeted investments in high-growth biotech and medical technologies.



About Biotech Capital Limited

Biotech Capital is a listed entity on the ASX and is a Pooled Development Fund, registered under the Pooled Development Funds Act 1992. The principal continuing activities of the Company consists of actively seeking new investment opportunities in the biotechnology and medical technology sectors.

Under the Pooled Development Funds Act 1992, shareholders are entitled to concessionary tax treatment in Australia for income and capital gains derived in connection with their shareholding. Gains realised on the disposal of shares will not be included in an investor's assessable income in Australia. An investor will not be entitled to any deduction or capital loss on the sale of shares. Unfranked dividends received by an Australian resident will be exempt from tax. Franked dividends will also be exempt from tax unless the shareholder elects to be taxed. An Australian corporate tax entity may credit its franking account (with franking credits attaching to a franked dividend), regardless of whether it has elected to treat the dividend as exempt or assessable income. Dividends paid to non-residents will not be subject to withholding tax. A shareholder or prospective shareholder should obtain their own tax advice rather than relying on this summary.

Forward-looking Statements

This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Biotech Capital to be materially different from the statements in this announcement.

For more information, please contact:

Dr Richard Treagus, Chairman
richard.treagus@bigpond.com
Tel: +61 417 520 509